Premium
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Author(s) -
Stahl Maximilian,
Zeidan Amer M.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30532
Subject(s) - medicine , histone deacetylase , hypomethylating agent , histone deacetylase inhibitor , myelodysplastic syndromes , clinical trial , pharmacology , cancer research , histone , genetics , dna methylation , biology , gene , bone marrow , gene expression
The combination of hypomethylating agents and histone deacetylase inhibitors demonstrates promising results in phase 1 trials but unfortunately disappointing results in all phase 2 trials to date. See also pages 994‐1002.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom